Zevra Therapeutics (ZVRA) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.
- Zevra Therapeutics' Consolidated Net Income rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
- Latest data reveals that Zevra Therapeutics reported Consolidated Net Income of -$544000.0 as of Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
- Zevra Therapeutics' Consolidated Net Income's 5-year high stood at $74.7 million during Q2 2025, with a 5-year trough of -$35.7 million in Q4 2024.
- Over the past 5 years, Zevra Therapeutics' median Consolidated Net Income value was -$10.3 million (recorded in 2021), while the average stood at -$5.6 million.
- In the last 5 years, Zevra Therapeutics' Consolidated Net Income skyrocketed by 62211.87% in 2021 and then crashed by 67438.79% in 2024.
- Quarter analysis of 5 years shows Zevra Therapeutics' Consolidated Net Income stood at -$2.7 million in 2021, then surged by 368.41% to $7.3 million in 2022, then crashed by 374.18% to -$19.9 million in 2023, then crashed by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.48% to -$544000.0 in 2025.
- Its last three reported values are -$544000.0 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.